Roger Stupp

TL;DR: Neoadjuvant docetaxel-cisplatin is effective and tolerable in stage IIIA pN2 NSCLC and downstaging to N0-1 at surgery was prognostic and significantly prolonged event-free survival (EFS) and overall survival (OS).

TL;DR: Recent developments in treatment of malignant glioma are summarized, focusing on the clinical management of patients in daily neuro-oncology practice, with particular focus on Oligodendroglioma with 1p/19q deletions.

TL;DR: Temozolomide demonstrated modest clinical efficacy, with an acceptable safety profile and measurable improvement in quality of life in patients with recurrent GBM, and should be explored further in an adjuvant setting and in combination with other agents.

TL;DR: There was no significant difference in outcome of the overall patient population treated with either radiotherapy alone or TMZ chemotherapy alone, and further data maturation is needed for overall survival analyses and evaluation of the full predictive impact of the molecular subtypes for individualized treatment choices.

TL;DR: A median survival of 23 months for patients undergoing EPP compares favourably with the survival reported from single center studies of upfront surgery, and the observed rate of operability is promising.